Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development

Glioblastoma (GBM) is an aggressive type of brain cancer with a poor prognosis for affected patients. The current line of treatment only gives the patients a survival time of on average 15 months. In this work, we use genome-scale metabolic models (GEMs) together with other systems biology tools to...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsson, Ida, Uhlén, Mathias, Zhang, Cheng, Mardinoglu, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181968/
https://www.ncbi.nlm.nih.gov/pubmed/32362913
http://dx.doi.org/10.3389/fgene.2020.00381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181968/
https://www.ncbi.nlm.nih.gov/pubmed/32362913
http://dx.doi.org/10.3389/fgene.2020.00381

Ejemplares similares